Immune checkpoint inhibitors, such as anti-PD-1 antibody, bind to the PD-1 expressed on activated cytotoxic T cells, thereby stimulating their proliferative capacity and enabling the immune system to resume recognizing, attacking, and destroying active cancer cells (100, 101). Here, PDCD1 is linked to cancer.